| Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM) T Cluzeau, M Sebert, R Rahmé, S Cuzzubbo, J Lehmann-Che, ... Journal of Clinical Oncology 39 (14), 1575, 2021 | 203 | 2021 |
| Germline DDX41 mutations define a significant entity within adult MDS/AML patients M Sébert, M Passet, A Raimbault, R Rahmé, E Raffoux, ... Blood, The Journal of the American Society of Hematology 134 (17), 1441-1444, 2019 | 171 | 2019 |
| Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia N Maslah, N Salomao, L Drevon, E Verger, N Partouche, P Ly, P Aubin, ... Haematologica 105 (6), 1539, 2020 | 118 | 2020 |
| APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A phase 2 study by the Groupe Francophone Des … T Cluzeau, M Sebert, R Rahmé, S Cuzzubbo, A Walter-petrich, P Peterlin, ... Blood 134, 677, 2019 | 81 | 2019 |
| Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort E Chiche, R Rahmé, S Bertoli, PY Dumas, JB Micol, Y Hicheri, F Pasquier, ... Blood Advances 5 (1), 176-184, 2021 | 73 | 2021 |
| Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients R Rahmé, X Thomas, C Recher, N Vey, J Delaunay, E Deconinck, ... Leukemia 28 (12), 2422-2424, 2014 | 57 | 2014 |
| FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias C Esnault, R Rahmé, KL Rice, C Berthier, C Gaillard, S Quentin, ... Blood, The Journal of the American Society of Hematology 133 (13), 1495-1506, 2019 | 42 | 2019 |
| Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic … DA Sallman, RS Komrokji, AE DeZern, M Sebert, G Garcia-Manero, ... Blood 138, 246, 2021 | 26 | 2021 |
| Outcome of older (≥ 70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study S Kayser, R Rahmé, D Martínez-Cuadrón, G Ghiaur, X Thomas, M Sobas, ... Leukemia 34 (9), 2333-2341, 2020 | 25 | 2020 |
| Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study S Kayser, RF Schlenk, D Lebon, M Carre, KS Götze, F Stölzel, ... haematologica 106 (12), 3100, 2021 | 16 | 2021 |
| Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy M Cerrano, M Duchmann, R Kim, L Vasseur, P Hirsch, X Thomas, ... Leukemia 35 (3), 712-723, 2021 | 14 | 2021 |
| Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report R Rahmé, E Benayoun, C Pautas, C Cordonnier, O Wagner-Ballon, ... Experimental Hematology 41 (6), 505-507, 2013 | 10 | 2013 |
| CPX-351 induces deep response and suppress the impact of poor prognosis mutations (TP53, ASXL1, RUNX1 and EVI1) defined by ELN-2017 in t-AML and MRC AML: a report from a … E Chiche, S Bertoli, R Rahmé, JB Micol, F Pasquier, P Peterlin, ... Blood 134, 1355, 2019 | 9 | 2019 |
| OncoAlert round table discussions: the global COVID-19 experience G Morgan, E de Azambuja, K Punie, F Ades, K Heinrich, N Personeni, ... JCO global oncology 7, 455-463, 2021 | 7 | 2021 |
| Lehmann che T Cluzeau, M Sebert, R Rahmé, S Cuzzubbo, A Walter-petrich J, 0 | 7 | |
| Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study C Willekens, R Rahme, M Duchmann, V Vidal, V Saada, S Broutin, ... Leukemia & lymphoma 62 (2), 438-445, 2021 | 6 | 2021 |
| Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a … R Rahmé, L Ades, X Thomas, A Guerci-Bresler, A Pigneux, N Vey, ... haematologica 103 (11), e519, 2018 | 6 | 2018 |
| Prognostic impact of clonal diversity in acute myeloid leukemia (AML) treated with intensive chemotherapy (IC) M Cerrano, M Passet, L Vasseur, P Hirsch, X Thomas, S Quentin, ... Blood 134, 2700, 2019 | 5 | 2019 |
| TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia R Rahmé, T Braun, JJ Manfredi, P Fenaux Biomedicines 11 (4), 1152, 2023 | 3 | 2023 |
| Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA±Venetoclax and CLAG-M: A Monocentric Experience R Rahmé, V Vidal, T Hueso, L Le Meur, M Rigal, S Ivanoff, S Brechignac, ... Blood 142, 1520, 2023 | 2 | 2023 |
